What we do Par Drugs & Chemicals Ltd manufactures active pharmaceutical ingredients and fine chemicals for domestic and international markets, with diversification into real estate, renewable energy, and capital markets. |
Founded in 1,999 |
Market share Established player with approx. 9,700 MTPA capacity across 4 manufacturing blocks, serving key pharma clients and exports. |
Problem solved Provides essential APIs and fine chemicals critical for pharmaceutical manufacturing; expanding into growth sectors for business resilience. |
Top clients or who we serve B2B focus; key clients include Pfizer Ltd., United Phosphorus Ltd., Essential Drugs Co. Ltd., and other pharma companies. |
Key management Mr. Falgun Vallabhbhai Savani (Chairman & MD), Mr. Jignesh Vallabhbhai Savani (CEO & Executive Director), both founders' family members. |
Our journey and innovations Founded in 1999, converted to public in 2018, IPO in 2019, expanded manufacturing capacity in 2021, now diversifying into new sectors. |
Where we operate Manufacturing in Bhavnagar, Gujarat; serves domestic India (approx. 75%) and international markets (approx. 25%). |
Top products or what we offer Manufacturing 12 APIs and 6 fine chemicals; major capacities in API blocks and magnesium hydroxide production. |
Top brands - |
Raw materials needed Chemical precursors for APIs and fine chemicals production. |
Raw materials supplier - |
Recurring vs cyclical contribution Revenue primarily from recurring sales of bulk drugs and chemicals; new verticals add investment-driven income. |
Our industry position Competitive in domestic API segment with export presence; newly entering real estate, clean energy, and capital market sectors. |
Financial highlights FY 2024-25 revenue ₹100.97 crore; net profit ₹13.36 crore; revenue grew by ~5.5% year-on-year; EPS at 10.86. |
Geographical revenue split Approximately 74.8% domestic, 25.2% international sales in FY 2024-25. |
Order book - |
Whats driving growth Capacity expansion and stable pharma demand; strategic diversification into real estate, renewable energy, and capital markets. |
Our future plans Divesting existing pharma unit and investing ₹27 crore each in real estate and clean energy, ₹41 crore in capital markets. |
Our green promise Entering clean and renewable energy sectors reflecting sustainability focus. |
Our people and values 121 employees with focus on training, compliance, and ethical standards. |
Key challenges ahead Managing transition with unit divestment, market competition, and diversification execution risks. |
Interesting facts Started as private in 1999, went public in 2018, and recently began broad business transformation. |
Risks and strategy Mitigating pharma market stagnation by entering high-growth sectors; strategic funding through divestment proceeds. |
